Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223

Scandinavian Journal of Urology

Volumn 49, Issue 3, 2015, Pages 211-217

  Nome, Ragnhild ^a   Hernes, Eivor ^b   Bogsrud, Trond Velde ^b,d   Bjøro, Trine ^a,c   Fosså, Sophie D ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alkaline phosphatases; Bone scan; Hormone resistant metastatic prostate cancer; PSA

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; FLUCICLOVINE F 18; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; RADIOISOTOPE; RADIUM; TUMOR MARKER;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE LESION; BONE METABOLISM; BONE METASTASIS; BONE SCINTISCANNING; CANCER GROWTH; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; BLOOD; BONE; BONE NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; SCINTISCANNING; SECONDARY; TREATMENT OUTCOME;

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; BIOMARKERS; BIOMARKERS, TUMOR; BONE AND BONES; BONE NEOPLASMS; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIONUCLIDE IMAGING; RADIOTHERAPY; RADIUM; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84988220653     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2014.982169     Document Type: Article

References (18)

1. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.
2. Pandit-Taskar N, Larson SM, Carrasquillo JA. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: alpha therapy with 223Ra-dichloride. J Nucl Med 2014;55:268-74.
3. Lorente JA, Valenzuela H, Morote J, Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 1999;26:625-32.
4. Kamiya N, Suzuki H, Endo T, Yano M, Naoi M, Nishimi D, et al. Clinical usefulness of bone markers in prostate cancer with bone metastasis. Int J Urol 2012;19:968-79.
5. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
6. Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer 2014;12:106-10.
7. Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa SD. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 2003;56:1397-404.
8. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
9. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
10. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001;27:187-92.
11. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-94.
12. Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castrationresistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2012;30:607-13.
13. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000;26:367-73.
14. Silberstein EB. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin Nucl Med 2005;35:152-8.
15. Cook G Jr., Parker C, Chua S, Johnson B, Aksnes AK, Lewington VJ. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res 2011;1:4.
16. Fossa SD, Heilo A, Lindegaard M, Skinningrud A, Ous S. Clinical significance of routine follow-up examinations in patients with metastatic cancer of the prostate under hormone treatment. Eur Urol 1983;9:262-6.
17. Croke J, Leung E, Segal R, Malone S. Clinical benefits of Alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review. BMJ Case Rep 2012;2012:12
18. Parker CC, Pascoe S, Chodacki A, O'Sullivan JM, Germa JR, O'Bryan-Tear CG, et al. A randomized, double-blind, dosefinding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013;63:189-97.